Amphenol maintains a Buy rating with a revised target price of $155, implying 17.7% upside driven by robust Q4 and full-year 2025 results. Click here to read more macro analysis here.
Earnings call Persimmon reported 2025 underlying PBT up 13% and EPS up 9%, driven by 12% higher completions and a 4% rise in average selling price. Management raised 2026 volume guidance to ...
Barclays 28th Annual Global Healthcare Conference March 10, 2026 9:30 AM EDTCompany ParticipantsWilliam McDowell - ...
Earnings call ASUS achieved all-time high 2025 revenue of TWD 688.9 billion (+26% YoY) and net profit of TWD 445.6 billion (+42% YoY), with Q4 results surpassing expectations. Management projects ...
Senior living providers are rethinking incentive packages for leadership in sales and operations in 2026, moving beyond base compensation payouts to ...
Every year, hundreds of startups are launched across Africa with bold promises to transform industries, disrupt markets, ...
Agentic AI could reshape drug development. In this interview, Dr. Claudio D’Ambrosio discusses how agentic AI can identify novel drug compounds, improve trial design, and reduce operational ...
Objectives This study aimed to investigate the knowledge, attitudes and practices (KAP) of patients with urinary calculi in China, where prior KAP research on this condition is lacking. Design A cross ...
Enterprise AI agents are often framed as a model problem. We’re told that the leap from building chatbots to agentic systems depends on better reasoning, larger context windows, and smarter benchmarks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results